FCM
GOSS icon

Farallon Capital Management’s Gossamer Bio GOSS Stock Holding History

Farallon Capital Management’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,130,272
Closed -$7.23M – 177
2024
Q1 		$7.23M Hold
6,130,272
– – 0.03% 97
2023
Q4 		$5.59M Hold
6,130,272
– – 0.03% 89
2023
Q3 		$5.11M Buy
+6,130,272
New +$7.06M 0.02% 98
2021
Q3 		– Sell
-202,326
Closed -$1.64M – 304
2021
Q2 		$1.64M Buy
+202,326
New +$1.75M 0.01% 213
2020
Q3 		– Sell
-100,000
Closed -$1.3M – 128
2020
Q2 		$1.3M Hold
100,000
– – 0.01% 117
2020
Q1 		$1.01M Sell
100,000
-400,000
-80% -$5.22M 0.01% 98
2019
Q4 		$7.82M Buy
500,000
+399,288
+396% +$8.04M 0.05% 103
2019
Q3 		$1.69M Buy
100,712
+712
+0.7% +$14.2K 0.01% 96
2019
Q2 		$2.22M Sell
100,000
-277,852
-74% -$5.32M 0.01% 99
2019
Q1 		$8.19M Buy
+377,852
New +$7.88M 0.06% 85

Other funds holding GOSS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Farallon Capital Management's GOSS Position: Q2 2024 in Review

Farallon Capital Management sold out of Gossamer Bio (GOSS) in Q2 2024, closing a stake of 6,130,272 shares — an estimated $7.23M sold.

Farallon Capital Management first reported a position in GOSS in Q1 2019 and held it in 10 quarters. The position peaked at $8.19M in Q1 2019. 94 funds tracked by Wall St. Rank hold GOSS as of Q2 2024.

  • Farallon Capital Management reported no remaining Gossamer Bio position as of Q2 2024 after selling out during the quarter.
  • Farallon Capital Management sold 6,130,272 Gossamer Bio shares in Q2 2024, an estimated $7.23M.
  • Farallon Capital Management first reported a position in Gossamer Bio in Q1 2019 and held it in 10 quarters.
  • Farallon Capital Management's Gossamer Bio position peaked at $8.19M in Q1 2019.
  • 94 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2024.

Based on Farallon Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.